Recombinant Mouse 4-1BB Ligand / TNFSF9 Protein, Fc Tag, 50 µg

Background
Tumor necrosis factor ligand superfamily member 9 (4-1BBL) is also known as 4-1BB ligand, CD137L or TNFSF9, which is a cytokine that binds to TNFRSF9. 4-1BBL is the high affinity ligand of 4-1BB. 4-1BBL induces the proliferation of activated peripheral blood T-cells. Also, 4-1BBL may have a role in activation-induced cell death (AICD). Furthermore, 4-1BBL may play a role in cognate interactions between T-cells and B-cells/macrophages. As for diseases, 4-1BBL is involved in cancers, infectious diseases and autoimmune diseases.

Source
Recombinant Mouse 4-1BB Ligand, Fc Tag (41L-M5257) is expressed from human 293 cells (HEK293). It contains AA Arg 104 - Glu 309 (Accession # NP_033430).
Predicted N-terminus: Arg 104

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 49.0 kDa. The protein migrates as 64-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma"
Yuti, Sawasdee, Natungnuy et al
Biomed Pharmacother (2023) 168, 115691
(2) "Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands"
Garman, Jiang, Daouti et al
Front Immunol (2023) 14, 1151748
(3) "Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"
Fromm, de Silva, Schreiber
Front Immunol (2023) 14, 1236332
Showing 1-3 of 765 papers.